Gyre Therapeutics shows a highly favorable modeled asymmetry and a recovering technical setup, but value-trap signals from margin compression, a confirmed prior downtrend, material insider selling, and the absence of a clear trading edge together support the recommendation to consider reducing the position.
Thesis pillars
- Value Trap Margin Compression→Stable
- Confirmed Technical Downtrend→Stable
- High Asymmetry Speculative Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Gyre Therapeutics, Inc. (GYRE) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Momentum 4.4/10 is below the 5.0 floor at $6.86 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Elevated risk factors; Below 200-MA, MA slope -3.1%/30d (confirmed downtrend).
Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ fibrosis and inflammatory disease, commercializing products in China through its majority-owned subsidiary Gyre Pharmaceuticals while running US clinical trials from... Read more
Sell if holding. Momentum 4.4/10 is below the 5.0 floor at $6.86 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Elevated risk factors; Below 200-MA, MA slope -3.1%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 68. Score 5.4/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Gyre Therapeutics, Inc.
About Gyre Therapeutics, Inc.
Gyre Therapeutics sells three approved fibrosis and liver-disease therapies in China, ETUARY (pirfenidone), Etorel (nintedanib) and Contiva (avatrombopag), which together generated $116.2 million in 2025 revenue, with ETUARY alone accounting for $106.1 million. The company's lead pipeline asset, Hydronidone, met its primary endpoint in a PRC Phase 3 trial for chronic hepatitis B-associated liver fibrosis and is advancing through Phase 1 testing in the United States for MASH.
Gyre Pharmaceuticals earns revenue by selling ETUARY, Etorel and Contiva to PRC hospitals and pharmacies, competing for placement through the government's centralized tender process and depending on continued inclusion on China's National Reimbursement Drug List for reimbursement support. ETUARY has held a leading position in the pulmonary fibrosis market since its 2017 NRDL listing, though its share has eroded as rival therapies such as OFEV (nintedanib), which generated $76.9 million in PRC sales in 2024, gain ground. Beyond the marketed portfolio, Gyre is funding a broader liver- and lung-disease pipeline, including F573 for acute liver failure (Phase 2), F230 for pulmonary arterial hypertension (Phase 1) and F528 for COPD (preclinical), alongside Hydronidone's parallel PRC and US development tracks. On March 2, 2026, the company agreed to acquire Cullgen Inc. in an all-stock deal valuing the target at approximately $300 million, a transaction it completed on May 4, 2026.
Show full overview
Gyre's revenue base carries acute single-product dependency: the 10-K states its business is significantly dependent on sales of ETUARY amid rising competition from rivals like OFEV, and the company acknowledges it may be unable to diversify away from that reliance despite launching Etorel and Contiva in 2025. The nearest catalyst that could change this is Hydronidone, which met its Phase 3 primary endpoint in China in May 2025, with 52.85% of treated patients achieving fibrosis regression versus 29.84% on placebo, and is targeted for an NDA submission seeking conditional approval in the first half of 2026.
See also: Healthcare · Biotechnology
From Gyre Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductETUARY® (pirfenidone)10-K Item 1A: 'Our business is significantly dependent on the sales of ETUARY®, one of our marketed products in the PRC'
Material Events(8-K, last 90d)
- 2026-05-04Item 2.01MEDIUMGyre Therapeutics completed its previously announced all-stock acquisition of Cullgen Inc., valuing Cullgen at approximately $300 million; Cullgen became a wholly owned subsidiary.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 4.4/10 is below the 5.0 floor at $6.86 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Elevated risk factors; Below 200-MA, MA slope -3.1%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 68. Prior stop was $6.38. Score 5.4/10, moderate confidence.
Take-profit target: $15.87 (+131.3% upside). Prior stop was $6.38. Stop-loss: $6.38.
Elevated risk factors; Below 200-MA, MA slope -3.1%/30d (confirmed downtrend); Value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.12% of cap).
Gyre Therapeutics, Inc. trades at a P/E of N/A (forward 121.0). TrendMatrix value score: 6.0/10. Verdict: Sell.
9 analysts cover GYRE with a consensus score of 4.2/5. Average price target: $19.
What does Gyre Therapeutics, Inc. do?Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ...
Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ fibrosis and inflammatory disease, commercializing products in China through its majority-owned subsidiary Gyre Pharmaceuticals while running US clinical trials from San Diego. Its three marketed drugs, ETUARY®, Etorel® and Contiva®, generated combined sales of $116.2 million in 2025, with ETUARY® alone contributing $106.1 million. The pipeline is led by Hydronidone, in Phase 3 for liver fibrosis in China and Phase 1 for MASH-associated liver fibrosis in the US.